Cargando…
Nonalcoholic Fatty Liver Disease After Pancreaticoduodenectomy for a Cancer Diagnosis
Purpose: Current literature reports increased incidence of postpancreaticoduodenectomy (PD) nonalcoholic fatty liver disease (NAFLD), a precursor for nonalcoholic steatohepatitis and cirrhosis. The incidence of and risk factors (RFs) for NAFLD in the PD population, however, are not well elucidated....
Autores principales: | , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Mary Ann Liebert, Inc., publishers
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8175252/ https://www.ncbi.nlm.nih.gov/pubmed/34095739 http://dx.doi.org/10.1089/pancan.2020.0006 |
_version_ | 1783703014701268992 |
---|---|
author | McGhee-Jez, Amy E. Chervoneva, Inna Yi, Misung Ahuja, Amisha Nahar, Ritu Shah, Samik Loh, Rebecca Houtmann, Sarah Shah, Rashesh Yeo, Charles J. Lavu, Harish Cohen, Steven J. Halegoua-DeMarzio, Dina Basu Mallick, Atrayee |
author_facet | McGhee-Jez, Amy E. Chervoneva, Inna Yi, Misung Ahuja, Amisha Nahar, Ritu Shah, Samik Loh, Rebecca Houtmann, Sarah Shah, Rashesh Yeo, Charles J. Lavu, Harish Cohen, Steven J. Halegoua-DeMarzio, Dina Basu Mallick, Atrayee |
author_sort | McGhee-Jez, Amy E. |
collection | PubMed |
description | Purpose: Current literature reports increased incidence of postpancreaticoduodenectomy (PD) nonalcoholic fatty liver disease (NAFLD), a precursor for nonalcoholic steatohepatitis and cirrhosis. The incidence of and risk factors (RFs) for NAFLD in the PD population, however, are not well elucidated. Methods: A cohort of 421 patients from a single institution who underwent PD for carcinoma and followed for at least 6 months were assessed retrospectively for age, gender, pathology, surgical complications (operative blood loss and length of stay [LOS]), comorbidities (diabetes, hypertension, hyperlipidemia, obesity), tobacco use, pre- and postoperative nutritional status (albumin and body mass index [BMI]), use of pancreatic enzyme replacement, and perioperative laboratory values (hemoglobin and liver function test). Cox proportional hazards model was used to examine these potential RFs as predictors of time to development of post-PD NAFLD. Results: Sixty (14.3%) patients developed post-PD NAFLD. Patients with NAFLD were younger (61.10 vs. 65.01 years old) and had higher preoperative BMI (28.92 vs. 26.61). Multivariate Cox proportional hazard model identified higher preoperative BMI, shorter postoperative LOS, and female gender as RFs for post-PD NAFLD. After excluding 12 patients with rare histology, there was a lower unadjusted hazard of developing NAFLD (p-value = 0.018) in the adenocarcinoma group than in the neuroendocrine and periampullary tumor groups. There was no statistically significant association between post-PD NAFLD and other characteristics. Conclusion: Female gender, higher preoperative BMI, and shorter LOS deserve closer monitoring for earlier detection and management of NAFLD. |
format | Online Article Text |
id | pubmed-8175252 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Mary Ann Liebert, Inc., publishers |
record_format | MEDLINE/PubMed |
spelling | pubmed-81752522021-06-04 Nonalcoholic Fatty Liver Disease After Pancreaticoduodenectomy for a Cancer Diagnosis McGhee-Jez, Amy E. Chervoneva, Inna Yi, Misung Ahuja, Amisha Nahar, Ritu Shah, Samik Loh, Rebecca Houtmann, Sarah Shah, Rashesh Yeo, Charles J. Lavu, Harish Cohen, Steven J. Halegoua-DeMarzio, Dina Basu Mallick, Atrayee J Pancreat Cancer Original Article Purpose: Current literature reports increased incidence of postpancreaticoduodenectomy (PD) nonalcoholic fatty liver disease (NAFLD), a precursor for nonalcoholic steatohepatitis and cirrhosis. The incidence of and risk factors (RFs) for NAFLD in the PD population, however, are not well elucidated. Methods: A cohort of 421 patients from a single institution who underwent PD for carcinoma and followed for at least 6 months were assessed retrospectively for age, gender, pathology, surgical complications (operative blood loss and length of stay [LOS]), comorbidities (diabetes, hypertension, hyperlipidemia, obesity), tobacco use, pre- and postoperative nutritional status (albumin and body mass index [BMI]), use of pancreatic enzyme replacement, and perioperative laboratory values (hemoglobin and liver function test). Cox proportional hazards model was used to examine these potential RFs as predictors of time to development of post-PD NAFLD. Results: Sixty (14.3%) patients developed post-PD NAFLD. Patients with NAFLD were younger (61.10 vs. 65.01 years old) and had higher preoperative BMI (28.92 vs. 26.61). Multivariate Cox proportional hazard model identified higher preoperative BMI, shorter postoperative LOS, and female gender as RFs for post-PD NAFLD. After excluding 12 patients with rare histology, there was a lower unadjusted hazard of developing NAFLD (p-value = 0.018) in the adenocarcinoma group than in the neuroendocrine and periampullary tumor groups. There was no statistically significant association between post-PD NAFLD and other characteristics. Conclusion: Female gender, higher preoperative BMI, and shorter LOS deserve closer monitoring for earlier detection and management of NAFLD. Mary Ann Liebert, Inc., publishers 2021-03-30 /pmc/articles/PMC8175252/ /pubmed/34095739 http://dx.doi.org/10.1089/pancan.2020.0006 Text en © Amy E. McGhee-Jez et al., 2021; Published by Mary Ann Liebert, Inc. https://creativecommons.org/licenses/by/4.0/This Open Access article is distributed under the terms of the Creative Commons License [CC-BY] (http://creativecommons.org/licenses/by/4.0 (https://creativecommons.org/licenses/by/4.0/) ), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Original Article McGhee-Jez, Amy E. Chervoneva, Inna Yi, Misung Ahuja, Amisha Nahar, Ritu Shah, Samik Loh, Rebecca Houtmann, Sarah Shah, Rashesh Yeo, Charles J. Lavu, Harish Cohen, Steven J. Halegoua-DeMarzio, Dina Basu Mallick, Atrayee Nonalcoholic Fatty Liver Disease After Pancreaticoduodenectomy for a Cancer Diagnosis |
title | Nonalcoholic Fatty Liver Disease After Pancreaticoduodenectomy for a Cancer Diagnosis |
title_full | Nonalcoholic Fatty Liver Disease After Pancreaticoduodenectomy for a Cancer Diagnosis |
title_fullStr | Nonalcoholic Fatty Liver Disease After Pancreaticoduodenectomy for a Cancer Diagnosis |
title_full_unstemmed | Nonalcoholic Fatty Liver Disease After Pancreaticoduodenectomy for a Cancer Diagnosis |
title_short | Nonalcoholic Fatty Liver Disease After Pancreaticoduodenectomy for a Cancer Diagnosis |
title_sort | nonalcoholic fatty liver disease after pancreaticoduodenectomy for a cancer diagnosis |
topic | Original Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8175252/ https://www.ncbi.nlm.nih.gov/pubmed/34095739 http://dx.doi.org/10.1089/pancan.2020.0006 |
work_keys_str_mv | AT mcgheejezamye nonalcoholicfattyliverdiseaseafterpancreaticoduodenectomyforacancerdiagnosis AT chervonevainna nonalcoholicfattyliverdiseaseafterpancreaticoduodenectomyforacancerdiagnosis AT yimisung nonalcoholicfattyliverdiseaseafterpancreaticoduodenectomyforacancerdiagnosis AT ahujaamisha nonalcoholicfattyliverdiseaseafterpancreaticoduodenectomyforacancerdiagnosis AT naharritu nonalcoholicfattyliverdiseaseafterpancreaticoduodenectomyforacancerdiagnosis AT shahsamik nonalcoholicfattyliverdiseaseafterpancreaticoduodenectomyforacancerdiagnosis AT lohrebecca nonalcoholicfattyliverdiseaseafterpancreaticoduodenectomyforacancerdiagnosis AT houtmannsarah nonalcoholicfattyliverdiseaseafterpancreaticoduodenectomyforacancerdiagnosis AT shahrashesh nonalcoholicfattyliverdiseaseafterpancreaticoduodenectomyforacancerdiagnosis AT yeocharlesj nonalcoholicfattyliverdiseaseafterpancreaticoduodenectomyforacancerdiagnosis AT lavuharish nonalcoholicfattyliverdiseaseafterpancreaticoduodenectomyforacancerdiagnosis AT cohenstevenj nonalcoholicfattyliverdiseaseafterpancreaticoduodenectomyforacancerdiagnosis AT halegouademarziodina nonalcoholicfattyliverdiseaseafterpancreaticoduodenectomyforacancerdiagnosis AT basumallickatrayee nonalcoholicfattyliverdiseaseafterpancreaticoduodenectomyforacancerdiagnosis |